Trial Profile
Impact of desensitization therapy in heart and lung transplant recipients treated with proteasome inhibitor carfilzomib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2015
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Heart-lung transplant rejection
- Focus Therapeutic Use
- 20 Aug 2015 New trial record